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Cells exposed to genotoxic insults such as ionizing radiation activate a signaling cascade to repair the
damaged DNA. Two recent articles published in Nature show that such genome maintenance requires modi-
fications of tumor suppressor proteins BRCA1 and 53BP1 by the small ubiquitin-like modifier SUMO.Proper genome maintenance, ensured by
the cellular DNA damage response (DDR)
machinery, is a prerequisite for normal
development and prevention of premature
aging and diverse devastating diseases
including cancer (Jackson and Bartek,
2009). Indeed, one reason for cancer inci-
dence not being even higher appears to be
the intrinsic ability of our cells to detect
and deal with the DNA damage caused
by exogenous genotoxic agents such as
radiation or chemicals as well as endoge-
nous sources such as oncogene-evoked
replication stress and telomere erosion
during the early stages of cancer develop-
ment (Halazonetis et al., 2008; Jackson
and Bartek, 2009). Even if some DNA
lesions, such as subsets of DNA double-
strand breaks (DSB) that occur commonly
during tumorigenesis, remain unrepaired,
sustained signaling and effector path-
ways within the DDR ‘‘anticancer barrier’’
machinery usually eliminate such haz-
ardous, genetically unstable cells by
inducing cell death or a permanent cell
cycle arrest known as cellular senescence
(Halazonetis et al., 2008).
From the mechanistic viewpoint, sens-
ing, signaling, and repair of DSBs involvea plethora of proteins whose sequential
accrual and function at the DNA damage
sites is modulated by a myriad of post-
translational modifications, including
phosphorylation, acetylation, methyla-
tion, and ubiquitylation, which are highly
dynamic and reversible. The phosphoryla-
tion/dephosphorylation events are per-
formed by kinases such as the ATM, ATR,
and DNA-PK, and several protein phos-
phatases (Jackson and Bartek, 2009). The
emerging ubiquitylation cascade com-
prises the E3 ubiquitin ligases RNF8,
RNF168, and BRCA1, as well as the E2
ubiquitin-conjugating enzyme UBC13 and
the candidate assembly factor HERC2
(Bergink and Jentsch, 2009; Bekker-Jen-
sen et al., 2010). Unlike the classical
role of ubiquitylation in triggering protein
degradation, however, this ubiquitin-medi-
ated pathway orchestrates protein-protein
interactions on damaged chromosomes
and recruitment of the key DNA repair fac-
tors 53BP1 and BRCA1 to DSBs, thereby
promoting genomic integrity (Figure 1).
Despite the rapid progress in under-
standing the molecular basis of DSB
signaling and repair, more surprises are
in store for us in this lively area ofresearch, as illustrated by two recent
reports in Nature (Galanty et al., 2009;
Morris et al., 2009). These exciting studies
provide evidence for a key role of yet
another protein modification, sumoylation
(covalent attachment of the small proteins
known as SUMO1, SUMO2, and SUMO3),
in coordinating the DNA damage re-
sponse to DSBs (Figure 1). Processes
critical for cell fate decisions including
survival and some aspects of DNA repair
have been linked to the sumoylation
pathway, particularly in yeast (Bergink
and Jentsch, 2009; Branzei and Foiani,
2008; Hay, 2005). However, the involve-
ment of the sumoylation pathway in DSB
response and its functional interplay with
the ubiquitylation cascade that controls
recruitment of 53BP1 and BRCA1 are
novel and very relevant for genome main-
tenance and protection against cancer.
So what is revealed by the two new
studies? First, in a complementary series
of immunofluorescence and live-cell imag-
ing experiments, they show that the
SUMO1 and SUMO2/3 conjugates, as
well as the E1 (SAE1), E2 (UBC9), and E3
(PIAS1 and PIAS4) sumoylation enzymes,
all rapidly accumulate at the sites of DNA17, January 19, 2010 ª2010 Elsevier Inc. 9
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Figure 1. Role of SUMOylation in DSB Signaling and Repair
Induction of DNA double-strand breaks (DSBs) by, for example, ionizing radiation (IR) or genotoxic chemotherapeutics leads to activation of the ATM kinase,
ATM-mediated phosphorylation (P) of histone H2AX, MDC1, Mre11-Rad50-NBSs1 complex and other proteins, and subsequent recruitment of, and signaling
by, the ubiquitin ligases RNF8 and RNF168. Coordinated ubiquitylation- (green) and SUMOylation-mediated (blue) signaling leads to focal modification of
chromatin and recruitment of repair proteins 53BP1 and the BRCA1/BARD1/Rap80 complex at DSBs, thereby setting the stage for efficient DNA repair. The
approximate timing of accrual and modifications of targets of the SUMO ligases PIAS1 and PIAS4, as reported by Galanty et al. (2009) and Morris et al.
(2009), are indicated. The role of this genome integrity mechanism as part of the intrinsic biological barrier against cancer is evident from the fact that numerous
components of this cascade are established (encircled in solid red) or candidate (broken red outline) tumor suppressors.
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Previewsdamage induced by ionizing radiation,
genotoxic anticancer drugs such as
cisplatin and hydroxyurea, or laser (Fig-
ure 1). Second, functional assays to
assess the phenotypes of human cells
depleted of the individual E3 enzymes
via RNA interference led to several con-
clusions. (1) PIAS1 is required for the
SUMO2/3 modifications at DSB sites and
sumoylation of the BRCA1 repair factor
and tumor suppressor whereas PIAS4
mediates mainly SUMO1 modifications
yet contributes also to SUMO2/3 conju-
gates and targets both the 53BP1 repair
factor and BRCA1. (2) The E3 ligases
PIAS1 and PIAS4 are also required for the
DSB-induced ubiquitylation events medi-
ated by the RNF8 and RNF168 ubiquitin
ligases, whose activities are essential for
efficient accrual of the downstream factors
53BP1 and the BRCA1/BARD1-Rap80
complex to DNA damage sites (Figure 1).
(3) Consistent with the above observa-
tions, PIAS1 and PIAS4 are necessary for
proficient DNA repair of DSBs, as docu-
mented by both impaired kinetics of DNA
repair and lower survival (enhanced sensi-
tivity) of PIAS1/4-depleted cells upon
exposure to various genotoxic insults.
What else have we learned about the
substrates and functional impact of
the SUMO modifications of proteins at10 Cancer Cell 17, January 19, 2010 ª2010 Ethe DSB sites? Apart from evidence that
both 53BP1 and BRCA1 become promptly
sumoylated during the DDR, in a PIAS4-
and PIAS1/4-dependent manner, respec-
tively (Galanty et al., 2009), Morris et al.
(2009) identified two consensus SUMO-
conjugation sites of BRCA1 and used
mutagenesis of these sites to document
their importance for BRCA1’s ubiquitin
ligase activity. These results led Morris
et al. (2009) to propose that BRCA1 is a
SUMO-regulated ubiqutin ligase. Perhaps
sumoylation could also guide BRCA1’s
ubiquitin ligase activity toward certain
substrates. In addition, the effects of
PIAS1/4 depletion on the activities of
RNF8/RNA168 raise the possibility that
these DSB-recruited ubiquitin ligases are
also sumoylated (Figure 1).
A host of burning questions are raised
by these new studies. How are the
PIAS1/4 enzymes recruited to DSB sites?
What is the significance of the E1 SAE1
phosphorylation by the damage-acti-
vated ATM/ATR kinases? What are
potential additional SUMO substrates
within the DSB signaling and repair
machinery, and what is the functional
significance of the SUMO modifications
of such substrates? Furthermore, given
the reversibility of sumoylation, how is
desumoylation of 53BP1, BRCA1, andlsevier Inc.other putative SUMO substrates by
SUMO-specific proteases at DSBs regu-
lated? Sumoylation can also play a role
in protein-protein interactions (through
SUMO-interacting motifs), and therefore
identification of such proteins at DNA
damage sites may be anticipated.
Apart from the mechanistic insight into
DSB processing, one striking feature of
this emerging complex pathway is its inti-
mate link with cancer. Thus, multiple
components of this cascade are tumor
suppressors (Figure 1), encoded by genes
whose germline loss-of-function muta-
tions predispose individuals to cancer
(Jackson and Bartek, 2009). More work
is needed to determine whether PIAS
enzymes are tumor suppressors, not least
because their cellular effects are pleio-
tropic and may be context specific (Hay,
2005; Rytinki et al., 2009). However, the
prominent role of PIAS4 in stress-induced
cellular senescence, the multiple ways
that PIAS ligases promote genome
stability, and SUMO-mediated regulation
of major tumor suppressors implicate the
sumoylation system in cellular defense
against tumorigenesis (Bischof et al.,
2006; Bergink and Jentsch, 2009; Rytinki
et al., 2009). This notion is also supported
by numerous reports on aberrant loss of
PIAS1/4 in various types of human cancer
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(2009) and Galanty et al. (2009) on regula-
tion of BRCA1 by PIAS1/4.
Last but not least, the new discoveries
of sumoylation pathways in DNA damage
response highlight the possibility to
modulate these activities in order to either
protect normal tissues from, or sensitize
cancer cells to, effects of genotoxic anti-
cancer therapies. The fact that the analo-
gous ubiquitylation system appears to be
‘‘drugable’’ and that even drugs that
affect pleiotropic mechanisms such as
the proteasome are proving useful in
cancer treatment offer some optimism
for such potential future applications.REFERENCES
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